Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

Seagen logo

About Seagen Stock (NASDAQ:SGEN)

Key Stats

Today's Range
$228.74
$228.74
50-Day Range
$228.74
$228.74
52-Week Range
$123.77
$228.96
Volume
N/A
Average Volume
1.48 million shs
Market Capitalization
$42.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SGEN Stock News Headlines

Pfizer raises guidance as COVID franchise drives Q3 beat
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance estimates it could unlock $400 trillion - but analyst Jeff Brown, who was consulted by Congressional offices on the legislation, believes the real figure could reach $2.6 quadrillion. Brown says this shift will pour onto a new type of investment exchange - and he's showing investors how to position themselves starting with just $100.tc pixel
Franklin Biotechnology Discovery C
Pfizer: Turning The Corner (Rating Upgrade)
See More Headlines

SGEN Stock Analysis - Frequently Asked Questions

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.33. The firm's revenue for the quarter was up 27.1% on a year-over-year basis.

Seagen subsidiaries include Cascadian Therapeutics.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), Meta Platforms (META), Intel (INTC), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE) and Qualcomm (QCOM).

Company Calendar

Last Earnings
11/01/2023
Today
8/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGEN
CIK
1060736
Employees
3,256
Year Founded
1998

Profitability

EPS (Trailing Twelve Months)
($4.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$610.31 million
Net Margins
-32.61%
Pretax Margin
-32.12%
Return on Equity
-28.06%
Return on Assets
-20.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.67
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$2.30 billion
Price / Sales
18.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$15.10 per share
Price / Book
15.15

Miscellaneous

Outstanding Shares
187,698,000
Free Float
139,084,000
Market Cap
$42.93 billion
Optionable
No Data
Beta
0.32

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:SGEN) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners